Immuron Limited (IMRN)
NASDAQ: IMRN · Real-Time Price · USD
1.900
-0.120 (-5.94%)
Feb 21, 2025, 4:00 PM EST - Market closed
Immuron Employees
Immuron had 7 employees as of June 30, 2024. The number of employees increased by 1 or 16.67% compared to the previous year.
Employees
7
Change (1Y)
1
Growth (1Y)
16.67%
Revenue / Employee
$467,313
Profits / Employee
-$661,192
Market Cap
11.64M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Jun 30, 2024 | 7 | 1 | 16.67% |
| Jun 30, 2023 | 6 | 1 | 20.00% |
| Jun 30, 2022 | 5 | -11 | -68.75% |
| Jun 30, 2014 | 16 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 440,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher Scientific | 122,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 72,000 |
IMRN News
- 5 weeks ago - Immuron Travelan® continued strong sales growth - GlobeNewsWire
- 5 weeks ago - Immuron Announces New Research Collaboration targeting Antimicrobial Resistance - GlobeNewsWire
- 5 weeks ago - Immuron Announces Travelan® Clinical Trial Update - GlobeNewsWire
- 2 months ago - Immuron CEO, Steven Lydeamore to Present at the Small Cap Growth Virtual Investor Conference December 5th - GlobeNewsWire
- 3 months ago - Immuron CEO, Steven Lydeamore presentation to 21st Virtual Investor Summit Microcap Event - GlobeNewsWire
- 3 months ago - Immuron Limited to Present at November 21st Virtual Investor Summit Microcap Event - Accesswire
- 4 months ago - Immuron CEO, Steven Lydeamore participation in Maxim Virtual Healthcare Conference - GlobeNewsWire
- 5 months ago - NMRC Reports Results for Campylobacter Controlled Human Infection Model Study - GlobeNewsWire